Drug
Bomedemstat clinical trials
Also written IMG-7289 and MK-3543.
- studies test it
- 16
- open now
- 5
- in phase 3
- 4
- first study started
- 2017
Keep track of what changes. Save the bomedemstat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 6
Merck Sharp & Dohme LLC (6) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (4) · Terrence J Bradley, MD (2) · The University of Texas Health Science Center at San Antonio (1) · United Lincolnshire Hospitals NHS Trust (1) · The University of Hong Kong (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bomedemstat is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07722611Written as Bomedemstat
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06351631Written as Bomedemstat
- Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisNot yet recruitingPhase 2United Lincolnshire Hospitals NHS TrustNCT07424950Written as bomedemstat
- Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Terrence J Bradley, MDNCT05597306Written as Bomedemstat
- Bomedemstat (IMG-7289) Plus Ruxolitinib for MyelofibrosisRecruitingPhase 2The University of Hong KongNCT05569538Written as Bomedemstat
- Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2Active, not recruitingPhase 2The University of Texas Health Science Center at San AntonioNCT04081220Written as IMG-7289
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Bomedemstat
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06456346Written as Bomedemstat
- A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05558696Written as Bomedemstat
- Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT04254978Written as Bomedemstat
- A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)CompletedPhase 1Merck Sharp & Dohme LLCNCT07049939Written as Bomedemstat
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)Active, not recruitingPhase 2Terrence J Bradley, MDNCT04262141Written as IMG-7289
- An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)CompletedPhase 2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05223920Written as Bomedemstat
- Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT06596668Written as bomedemstat
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2University of WashingtonNCT05191797Written as Bomedemstat
- Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)CompletedPhase 1/2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT03136185Written as Bomedemstat
Given in every arm · 1 — bomedemstat is usual care beside what is tested
Codes
What other systems call bomedemstat · ClinicalTrials.gg INT002068
- MeSH (NLM) C000730033bomedemstatOne source ClinicalTrials.gov
- UNII (FDA) Y2T4ALDEATBOMEDEMSTATConfirmed FDA, Wikidata
- Wikidata Q118727468bomedemstatConfirmed FDA, Wikidata
- NCI Thesaurus C131827BomedemstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730033 | bomedemstat | One source ClinicalTrials.gov |
| UNII (FDA) | Y2T4ALDEAT | BOMEDEMSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q118727468 | bomedemstat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C131827 | Bomedemstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.